OccuRx, a Melbourne-based biopharmaceutical company, was established in 2014 with venture funding from the Medical Research Commercialisation Fund, Brandon Capital Partners and Uniseed. The Company’s primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders. There is a high unmet clinical need for novel and cost effective products to enhance visual acuity and prevent vision loss in individuals with diabetes. OccuRx has patented a library of new chemical entities with potent anti-inflammatory and anti-fibrotic properties to treat diabetic retinopathy and other diseases of the retina.